Growth Hormone Disorders Recruiting Phase 2 Trials for Somapacitan (DB15093)

Also known as: Growth Hormone Disorder

IndicationStatusPhase
DBCOND0036845 (Growth Hormone Disorders)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02616562Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone DeficiencyTreatment